These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 29472354)

  • 1. Efficacy and safety of high-dose etoposide cytarabine as consolidation following rituximab methotrexate temozolomide induction in newly diagnosed primary central nervous system lymphoma in immunocompetent patients.
    Birsen R; Willems L; Pallud J; Blanc E; Burroni B; Legoff M; Le Ray E; Pilorge S; Deau B; Franchi P; Vignon M; Kirova Y; Edjlali M; Houillier C; Soussain C; Varlet P; Dezamis E; Damotte D; Bouscary D; Tamburini J
    Haematologica; 2018 Jul; 103(7):e296-e299. PubMed ID: 29472354
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI.
    Wieduwilt MJ; Valles F; Issa S; Behler CM; Hwang J; McDermott M; Treseler P; O'Brien J; Shuman MA; Cha S; Damon LE; Rubenstein JL
    Clin Cancer Res; 2012 Feb; 18(4):1146-55. PubMed ID: 22228634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methotrexate-cytarabine-dexamethasone combination chemotherapy with or without rituximab in patients with primary central nervous system lymphoma.
    Sun X; Liu J; Wang Y; Bai X; Chen Y; Qian J; Zhu H; Liu F; Qiu X; Sun S; Ji N; Liu Y
    Oncotarget; 2017 Jul; 8(30):49156-49164. PubMed ID: 28467782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methotrexate- and/or cytarabine-based chemotherapy may be effective and safe in solid-organ transplant recipients with primary central nervous system lymphomas.
    Moise L; Matta C; Hanna C; Pilorge S; Fermé C; Durrbach A; Ribrag V
    Leuk Lymphoma; 2011 Mar; 52(3):521-4. PubMed ID: 21133726
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical outcomes of etoposide and cytarabine as consolidation in elderly patients with primary CNS lymphoma.
    Kim YR; Cho H; Kim SJ; Chung H; Kook HW; Jang JE; Cheong JW; Kim JS
    Oncologist; 2024 Jun; 29(6):e796-e802. PubMed ID: 38581718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis.
    Abrey LE; Moskowitz CH; Mason WP; Crump M; Stewart D; Forsyth P; Paleologos N; Correa DD; Anderson ND; Caron D; Zelenetz A; Nimer SD; DeAngelis LM
    J Clin Oncol; 2003 Nov; 21(22):4151-6. PubMed ID: 14615443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcomes of patients with newly diagnosed primary central nervous system lymphoma are comparable on treatment with high-dose methotrexate plus temozolomide and with high-dose methotrexate plus cytarabine: a single-institution experience.
    Wang XX; Huang HQ; Bai B; Cai QQ; Cai QC; Gao Y; Xia YF; Xia ZJ; Jiang WQ
    Leuk Lymphoma; 2014 Nov; 55(11):2497-501. PubMed ID: 24605911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial.
    Thiel E; Korfel A; Martus P; Kanz L; Griesinger F; Rauch M; Röth A; Hertenstein B; von Toll T; Hundsberger T; Mergenthaler HG; Leithäuser M; Birnbaum T; Fischer L; Jahnke K; Herrlinger U; Plasswilm L; Nägele T; Pietsch T; Bamberg M; Weller M
    Lancet Oncol; 2010 Nov; 11(11):1036-47. PubMed ID: 20970380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary central nervous system lymphoma (PCNSL) in the elderly: a LOC network study.
    Houillier C; Ghesquières H; Chabrot C; Soussain C; Ahle G; Choquet S; Nicolas-Virelizier E; Bay JO; Vargaftig J; Gaultier C; Touitou V; Martin-Duverneuil N; Cassoux N; Le Garff-Tavernier M; Costopoulos M; Faurie P; Hoang-Xuan K
    J Neurooncol; 2017 Jun; 133(2):315-320. PubMed ID: 28432587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix).
    Schorb E; Finke J; Ferreri AJ; Ihorst G; Mikesch K; Kasenda B; Fritsch K; Fricker H; Burger E; Grishina O; Valk E; Zucca E; Illerhaus G
    BMC Cancer; 2016 Apr; 16():282. PubMed ID: 27098429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial.
    Omuro A; Chinot O; Taillandier L; Ghesquieres H; Soussain C; Delwail V; Lamy T; Gressin R; Choquet S; Soubeyran P; Huchet A; Benouaich-Amiel A; Lebouvier-Sadot S; Gyan E; Touitou V; Barrié M; del Rio MS; Gonzalez-Aguilar A; Houillier C; Delgadillo D; Lacomblez L; Tanguy ML; Hoang-Xuan K
    Lancet Haematol; 2015 Jun; 2(6):e251-9. PubMed ID: 26688235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined treatment with high-dose methotrexate, vincristine and procarbazine, without intrathecal chemotherapy, followed by consolidation radiotherapy for primary central nervous system lymphoma in immunocompetent patients.
    Ferreri AJ; Reni M; Dell'Oro S; Ciceri F; Bernardi M; Camba L; Ponzoni M; Terreni MR; Tomirotti M; Spina M; Villa E
    Oncology; 2001; 60(2):134-40. PubMed ID: 11244328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas.
    Wong ET; Tishler R; Barron L; Wu JK
    Cancer; 2004 Jul; 101(1):139-45. PubMed ID: 15221999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How important is whole brain radiotherapy for treatment of primary CNS lymphoma?
    Cabanillas F
    Lancet Oncol; 2010 Nov; 11(11):1011-2. PubMed ID: 20970379
    [No Abstract]   [Full Text] [Related]  

  • 15. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
    Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
    Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myeloablative vs nonmyeloablative consolidation for primary central nervous system lymphoma: results of Alliance 51101.
    Batchelor TT; Giri S; Ruppert AS; Geyer SM; Smith SE; Mohile N; Swinnen LJ; Friedberg JW; Kahl BS; Bartlett NL; Hsi ED; Cheson BD; Wagner-Johnston N; Nayak L; Leonard JP; Rubenstein JL
    Blood Adv; 2024 Jun; 8(12):3189-3199. PubMed ID: 38598710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A focus on pharmacotherapy for primary central nervous system lymphoma.
    Korfel A
    Expert Rev Hematol; 2015 Oct; 8(5):559-62. PubMed ID: 26159859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose-Adjusted EPOCH-R and Mid-Cycle High Dose Methotrexate for Patients with Systemic Lymphoma and secondary CNS Involvement.
    Chihara D; Fowler NH; Oki Y; Fanale MA; Fayad LE; Westin JR; Hagemeister FB
    Br J Haematol; 2017 Dec; 179(5):851-854. PubMed ID: 27502933
    [No Abstract]   [Full Text] [Related]  

  • 19. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
    Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
    Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Consecutive single-institution case series of primary central nervous system lymphoma treated by R-MPV or high-dose methotrexate monotherapy.
    Sasaki N; Kobayashi K; Saito K; Shimizu S; Suzuki K; Lee J; Yamagishi Y; Shibahara J; Takayama N; Shiokawa Y; Nagane M
    Jpn J Clin Oncol; 2020 Sep; 50(9):999-1008. PubMed ID: 32469065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.